journal
MENU ▼
Read by QxMD icon Read
search

Therapeutic Advances in Psychopharmacology

journal
https://read.qxmd.com/read/30800284/trends-in-the-scientific-literature-on-atypical-antipsychotic-drugs-in-the-united-kingdom-a-bibliometric-study
#1
REVIEW
Francisco López-Muñoz, Derek K Tracy, F Javier Povedano-Montero, Josefien Breedvelt, Javier García-Pacios, Mª Poveda Fernández-Martín, Gabriel Rubio, Cecilio Álamo
Objective: A bibliometric study was undertaken of peer-reviewed publications on atypical antipsychotic drugs (AADs) from the United Kingdom and the findings are presented herein. Methods: We selected the documents from the Scopus database. We applied several production and dispersion bibliometric indicators, including Price's law on the growth of the scientific literature, and Bradford's law. We also calculated a so-called 'participation index' across different countries...
2019: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/30800283/genetic-risk-factors-for-eating-disorders-an-update-and-insights-into-pathophysiology
#2
REVIEW
Hubertus Himmerich, Jessica Bentley, Carol Kan, Janet Treasure
Genome-wide-association studies (GWASs), epigenetic, gene-expression and gene-gene interaction projects, nutritional genomics and investigations of the gut microbiota have increased our knowledge of the pathophysiology of eating disorders (EDs). However, compared with anorexia nervosa, genetic studies in patients with bulimia nervosa and binge-eating disorder are relatively scarce, with the exception of a few formal genetic and small-sized candidate-gene-association studies. In this article, we review important findings derived from formal and molecular genetics in order to outline a genetics-based pathophysiological model of EDs...
2019: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/30524704/clozapine-hiv-and-neutropenia-a-case-report
#3
Eromona Whiskey, David O'Flynn, David Taylor
There is paucity of information on the use of clozapine in patients with HIV. Ethnicity, co-prescribed medications and possible drug-drug interactions are important considerations in evaluating risk of blood dyscrasias during clozapine treatment. Individuals with HIV should not be denied access to the most effective antipsychotic, but a multidisciplinary approach is essential for optimal outcome in such complex patients.
December 2018: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/30524703/medication-nonadherence-in-bipolar-disorder-a-narrative-review
#4
REVIEW
Ibrahim Jawad, Stuart Watson, Peter M Haddad, Peter S Talbot, R Hamish McAllister-Williams
A number of effective maintenance medication options exist for bipolar disorder (BD) and these are regarded as the foundation of long-term treatment in BD. However, nonadherence to medication is common in BD. For example, a large data base study in the United States of America (USA) showed that approximately half of patients with BD were nonadherent with lithium and maintenance medications over a 12 month period. Such nonadherence carries a high risk of relapse due to the recurrent nature of the illness and the fact that abrupt cessation of treatment, particularly lithium, may cause rebound depression and mania...
December 2018: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/30524702/anti-cytokine-agents-for-anhedonia-targeting-inflammation-and-the-immune-system-to-treat-dimensional-disturbances-in-depression
#5
REVIEW
Yena Lee, Mehala Subramaniapillai, Elisa Brietzke, Rodrigo B Mansur, Roger C Ho, Samantha J Yim, Roger S McIntyre
The etiology of mood disorders is mechanistically heterogeneous, underscoring the need for a dimensional approach to identify and develop targeted treatments in psychiatry. Accumulating evidence implicates inflammation as an important contributor to the pathophysiology of depression and presents the immune system as a viable therapeutic target that may be more proximate to the pathogenic nexus of brain-based disorders in specific subpopulations. Anhedonia is a transdiagnostic (e.g. Parkinson's disease, diabetes mellitus, rheumatic diseases), yet specific, and clinically relevant symptom dimension subserved by well-characterized neurobiological and neurophysiological substrates of the positive valence systems (PVS)...
December 2018: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/30524701/first-generation-versus-second-generation-long-acting-injectable-antipsychotic-drugs-and-time-to-relapse
#6
James M Stone, Simon Roux, David Taylor, Paul D Morrison
Background: The development of long-acting injectable formulations (LAIs) of second-generation antipsychotic drugs (SGAs) has been suggested as having advantage over first-generation antipsychotic (FGA) LAIs. In this study, we investigated the hypothesis that there was a longer time to relapse in patients with schizophrenia started on SGA LAI versus FGA LAI. Methods: Patients with a diagnosis of schizophrenia or schizoaffective disorder who were started on an SGA LAI while on an inpatient ward were identified through searching of the anonymised historical medical records at the South London and Maudsley NHS Foundation Trust...
December 2018: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/30524700/novel-developments-in-therapeutic-advances-in-psychopharmacology
#7
EDITORIAL
Hemi Malkki, David Taylor
No abstract text is available yet for this article.
December 2018: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/30346444/corrigendum
#8
(no author information available yet)
[This corrects the article DOI: 10.1177/2045125318782694.].
November 2018: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/30344998/are-structural-brain-changes-in-schizophrenia-related-to-antipsychotic-medication-a-narrative-review-of-the-evidence-from-a-clinical-perspective
#9
REVIEW
Stephen M Lawrie
Some observational studies and literature reviews suggest that antipsychotic drug use is associated with loss of grey or white matter in patients with schizophrenia, whereas others have contradicted this finding. Here, I summarize and critique the available evidence and put it in the context of clinical practice. This narrative review pools evidence from observational and experimental studies in humans and animals on the relationship between antipsychotic medication use and brain structure and function in patients with schizophrenia...
November 2018: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/30344997/the-acute-efficacy-of-antipsychotics-in-schizophrenia-a-review-of-recent-meta-analyses
#10
REVIEW
Peter M Haddad, Christoph U Correll
Schizophrenia is the eighth leading cause of disability worldwide in people aged 15-44 years. Before antidopaminergic antipsychotics were introduced in the 1950s, no effective medications existed for the treatment of schizophrenia. This review summarizes key meta-analytic findings regarding antipsychotic efficacy in the acute treatment of schizophrenia, including clozapine in treatment-resistant patients. In the most comprehensive meta-analysis of randomized controlled trials conducted in multi-episode schizophrenia, antipsychotics outperformed placebo regarding total symptoms, positive symptoms, negative symptoms, depressive symptoms, quality of life and social functioning...
November 2018: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/30344996/real-world-effectiveness-of-long-acting-antipsychotic-treatments-in-a-nationwide-cohort-of-3957-patients-with-schizophrenia-schizoaffective-disorder-and-other-diagnoses-in-quebec
#11
Emmanuel Stip, Jean Lachaine
Background: Long-acting injectable antipsychotics (LAI-AP) for patients with schizophrenia (SCZ) have saved significant healthcare costs. However, the cost effectiveness of LAI-AP for patients with other mental disorders has yet to be established. The goal of this study was to evaluate the impact of early initiation of LAI-AP medications on healthcare resource utilization (HRU). Drawing on the Quebecois universal healthcare program (RAMQ), we conducted a nationwide prospective cohort study of LAI-AP under real-world conditions...
November 2018: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/30210778/tarc-turkish-aripiprazole-consensus-report-aripiprazole-use-and-switching-from-other-antipsychotics-to-aripiprazole-consensus-recommendations-by-a-turkish-multidisciplinary-panel
#12
REVIEW
Baybars Veznedaroglu, Nesrin Dilbaz, Ozcan Uzun, Erdal Isik
In this review, we have attempted to share our 10 years' clinical experience with aripiprazole use and switching from other antipsychotics to aripiprazole. There are various reasons for switching, including a partial or complete lack of efficacy, adverse side effects, and partial or noncompliance with medication. Aripiprazole has some unique receptor-binding qualities that provides some advantages over other antipsychotics in certain clinical situations. We have covered potential clinical scenarios for aripiprazole use as a single agent and switching from other agents in inpatient and outpatient settings...
October 2018: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/30181867/epidemiology-and-risk-factors-for-bipolar-disorder
#13
REVIEW
Tobias A Rowland, Steven Marwaha
Bipolar disorder is a multifactorial illness with uncertain aetiology. Knowledge of potential risk factors enables clinicians to identify patients who are more likely to develop bipolar disorder, which directs further investigation, follow up and caution when prescribing. Ideally, identifying directly causative factors for bipolar disorder would enable intervention on an individual or population level to prevent the development of the illness, and improve outcomes through earlier treatment. This article reviews the epidemiology of bipolar disorder, along with putative demographic, genetic and environmental risk factors, while assessing the strength of these associations and to what extent they might be said to be 'causative'...
September 2018: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/30181866/haloperidol-decanoate-long-acting-injection-hdlai-results-of-a-1-year-mirror-image-study
#14
Shubhra Mace, Olubanke Dzahini, Maria O'Hagan, David Taylor
Background: We sought to determine clinical outcomes of the prescribing of haloperidol decanoate long-acting injection (HDLAI) at 1 year. Method: A 1-year mirror-image study of 84 inpatients initiated on HDLAI. Admissions and bed days in the year preceding HDLAI were compared with the year after initiation. Predictors for discontinuation were evaluated. Results: At 1 year, 33% of patients remained on treatment. Patients starting HDLAI because of nonadherence were more likely to stop treatment [relative risk (RR) 1...
September 2018: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/30065814/dilemmas-in-the-treatment-of-early-onset-first-episode-psychosis
#15
REVIEW
Daniel Hayes, Marinos Kyriakopoulos
Early-onset first-episode psychosis (EOP) is a severe mental disorder that can pose a number of challenges to clinicians, young people and their families. Its assessment and differentiation from other neurodevelopmental and mental health conditions may at times be difficult, its treatment may not always lead to optimal outcomes and can be associated with significant side effects, and its long-term course and prognosis seem to be less favourable compared with the adult-onset disorder. In this paper, we discuss some dilemmas associated with the evaluation and management of EOP and propose approaches that can be used in the clinical decision-making process...
August 2018: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/30065813/predicting-rehospitalization-in-patients-treated-with-antipsychotics-a-prospective-observational-study
#16
Heshu Abdullah-Koolmees, Helga Gardarsdottir, Lotte A Minnema, Kamjar Elmi, Lennart J Stoker, Judith Vuyk, Laurette E Goedhard, Toine C G Egberts, Eibert R Heerdink
Background: Prediction of rehospitalization in patients treated with antipsychotics is important for identifying patients in need of additional support to prevent hospitalization. Our aim was to identify factors that predict rehospitalization in patients treated with antipsychotics at discharge from a psychiatric hospital. Methods: Adult patients suffering from schizophrenia, psychotic or bipolar I disorders who had been hospitalized in a psychiatric hospital for ⩾7 days and were treated with oral antipsychotics at discharge were included...
August 2018: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/29977520/psychiatric-manifestations-in-wilson-s-disease-possibilities-and-difficulties-for-treatment
#17
REVIEW
Tomasz Litwin, Petr Dusek, Tomasz Szafrański, Karolina Dzieżyc, Anna Członkowska, Janusz K Rybakowski
Wilson's disease (WD) is an inherited metabolic disorder related to disturbances of copper metabolism, and predominantly presents with liver and neuropsychiatric symptoms. In most cases it can be successfully treated with anti-copper agents, and both liver function and neuropsychiatric symptoms typically improve. Treatment guidelines for WD include recommendations for anti-copper treatment as well as for the treatment of liver failure symptoms. Recently, recommendations for treatment of the neurological symptoms of WD have also been proposed...
July 2018: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/29977519/amisulpride-augmentation-of-clozapine-for-treatment-refractory-schizophrenia-a-double-blind-placebo-controlled-trial
#18
Thomas R E Barnes, Verity Leeson, Carol Paton, Louise Marston, David P Osborn, Raj Kumar, Patrick Keown, Rameez Zafar, Khalid Iqbal, Vineet Singh, Pavel Fridrich, Zachary Fitzgerald, Hemant Bagalkote, Peter M Haddad, Mariwan Husni, Tim Amos
Background: A second antipsychotic is commonly added to clozapine to treat refractory schizophrenia, notwithstanding the limited evidence to support such practice. Methods: The efficacy and adverse effects of this pharmacological strategy were examined in a double-blind, placebo-controlled, 12-week randomized trial of clozapine augmentation with amisulpride, involving 68 adults with treatment-resistant schizophrenia and persistent symptoms despite a predefined trial of clozapine...
July 2018: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/29977518/rethinking-the-spectrum-of-mood-disorders-implications-for-diagnosis-and-management-proceedings-of-a-symposium-presented-at-the-30th-annual-european-college-of-neuropsychopharmacology-congress-4-september-2017-paris-france
#19
REVIEW
Roger S McIntyre, Allan H Young, Peter M Haddad
The simultaneous occurrence of manic and depressive features has been recognized since classical times, but the term 'mixed state' was first used by Kraepelin at the end of the 19th century. From the 1980s, until the advent of the Diagnostic and Statistical Manual of Mental Disorders , fifth edition (DSM-5), psychiatric disorders were classified using a categorical approach. However, it was recognized that such an approach was too rigid to encompass the range of symptomatology encountered in clinical practice...
June 2018: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/29854396/switching-and-augmentation-strategies-for-antipsychotic-medications-in-acute-phase-schizophrenia-latest-evidence-and-place-in-therapy
#20
REVIEW
Kotaro Hatta, Naoya Sugiyama, Hiroto Ito
In terms of effectiveness of antipsychotics in schizophrenia, discrepancy often exists between results from double-blind randomized controlled trials and observations in emergency or acute-phase clinical practice. For instance, the antipsychotic switching strategy is not always applicable in emergency or acute-phase situations, and augmentation of another antipsychotic is occasionally done instead. In this review, we discuss strategies for early nonresponse to an antipsychotic drug such as switching and augmentation from the perspective of emergency and acute-phase treatment...
June 2018: Therapeutic Advances in Psychopharmacology
journal
journal
43489
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"